| 1.91 -0.02 (-1.04%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.24 | 1-year : | 2.3 |
| Resists | First : | 1.92 | Second : | 1.97 |
| Pivot price | 1.92  |
|||
| Supports | First : | 1.85 | Second : | 1.53 |
| MAs | MA(5) : | 1.92 | MA(20) : | 1.91 |
| MA(100) : | 1.02 |
MA(250) : | 0.99 |
|
| MACD | MACD : | 0.1  |
Signal : | 0.1 |
| %K %D | K(14,3) : | 44.6 |
D(3) : | 59.8 |
| RSI | RSI(14): 67.2 | |||
| 52-week | High : | 2.64 | Low : | 0.48 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DRRX ] has closed above bottom band by 24.7%. Bollinger Bands are 85.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.91 - 1.92 | 1.92 - 1.93 |
| Low: | 1.89 - 1.9 | 1.9 - 1.91 |
| Close: | 1.89 - 1.91 | 1.91 - 1.93 |
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Thu, 11 Sep 2025
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio - PR Newswire
Tue, 26 Aug 2025
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025 - Yahoo Finance
Fri, 22 Aug 2025
DURECT Corporation Stock (DRRX) Opinions on Potential Acquisition by Bausch Health | DRRX Stock News - Quiver Quantitative
Tue, 12 Aug 2025
Biotech DURECT Gets $63M Buyout Offer from Bausch Health with $350M Future Payment Potential - Stock Titan
Fri, 08 Aug 2025
Bausch Health to Acquire DURECT Corporation in $63M Deal to Advance Liver Disease Treatment - Yahoo Finance
Wed, 30 Jul 2025
Bausch Health expands liver disease portfolio with DURECT Corp buy - The Pharma Letter
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 31 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 12.6 (%) |
| Held by Institutions | 23.5 (%) |
| Shares Short | 345 (K) |
| Shares Short P.Month | 401 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | -209.9 % |
| Operating Margin | -627.1 % |
| Return on Assets (ttm) | -45.4 % |
| Return on Equity (ttm) | -307.4 % |
| Qtrly Rev. Growth | -30.8 % |
| Gross Profit (p.s.) | 0.13 |
| Sales Per Share | 0.05 |
| EBITDA (p.s.) | -0.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -4.45 |
| PEG Ratio | 0 |
| Price to Book value | 17.36 |
| Price to Sales | 35.72 |
| Price to Cash Flow | -4.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|